News
Asianet Newsable on MSN21m
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...
The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback